Idarucizumab (Praxbind)

The First Reversal Agent for a Direct Oral Anticoagulant

Research output: Contribution to journalEditorial

4 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)e195-e197
JournalAmerican Journal of Medicine
Volume130
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Anticoagulants
idarucizumab

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Idarucizumab (Praxbind) : The First Reversal Agent for a Direct Oral Anticoagulant. / Finks, Shannon; Rogers, Kelly.

In: American Journal of Medicine, Vol. 130, No. 5, 01.05.2017, p. e195-e197.

Research output: Contribution to journalEditorial

@article{6085ba7e1b6d429992d20149fb47ca73,
title = "Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant",
author = "Shannon Finks and Kelly Rogers",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.amjmed.2016.11.029",
language = "English (US)",
volume = "130",
pages = "e195--e197",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Idarucizumab (Praxbind)

T2 - The First Reversal Agent for a Direct Oral Anticoagulant

AU - Finks, Shannon

AU - Rogers, Kelly

PY - 2017/5/1

Y1 - 2017/5/1

UR - http://www.scopus.com/inward/record.url?scp=85011068075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011068075&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2016.11.029

DO - 10.1016/j.amjmed.2016.11.029

M3 - Editorial

VL - 130

SP - e195-e197

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -